B Chevallier

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

René Bruno, Darcy A. Hille, A. Riva et al. · Journal of Clinical Oncology · 1998 · 423 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.

B Chevallier, Henri Roché, Jean Pierre Olivier et al. · PubMed · 1993 · 269 citations

Medicine, Oncology, Radiation Oncology +17

Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.

B Chevallier, P. Fumoleau, Pierre Kerbrat et al. · Journal of Clinical Oncology · 1995 · 223 citations

Medicine, Oncology, Pharmacology +16

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

Matti Aapro, F.H. van Wijk, Giorgio Bolis et al. · Annals of Oncology · 2003 · 200 citations · Full text

Medicine, Gynecology, Oncology +8

Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.

B Chevallier, P. Chollet, Yacine Merrouche et al. · Journal of Clinical Oncology · 1995 · 124 citations

Medicine, Oncology, Pharmacology +16